BioSight
Companies
Neurogene Inc. logo

NGNE

NASDAQNEW YORK, NY
Neurogene Inc.

Neurogene develops gene therapy treatments for neurological diseases. The company's most advanced program, NGN-401, is currently in clinical trials, while other product candidates remain in early-stage development. Neurogene has not completed any clinical trials or received regulatory approval for any product, has generated no product revenue to date, and has incurred significant losses since inception.

Price history not yet available for NGNE.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar